{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260630626667/en/Stoke-Therapeutics-Announces-Completion-of-Enrollment-of-162-Patients-Into-the-Phase-3-EMPEROR-Study-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome", "message": "News view counter 822828 successfully enlarged"}